Peer-reviewed Research Articles:
1. Kalish RB, Vardhana S, Gupta M, Chasen ST, Perni SC, Witkin SS. Interleukin-1 receptor antagonist gene polymorphism and multifetal pregnancy outcome. Am J Obstet Gynecol. 2003 Oct;189(4):911-4. PubMed PMID: 14586324. https://www.ncbi.nlm.nih.gov/pubmed/14586324.
2. Witkin SS, Vardhana S, Yih M, Doh K, Bongiovanni AM, Gerber S. Polymorphism in intron 2 of the fetal interleukin-1 receptor antagonist genotype influences midtrimester amniotic fluid concentrations of interleukin-1beta and interleukin-1 receptor antagonist and pregnancy outcome. Am J Obstet Gynecol. 2003 Nov;189(5):1413-7. PMID: 14634579. https://www.ncbi.nlm.nih.gov/pubmed/14634579.
3. Kalish RB, Vardhana S, Gupta M, Perni SC, Witkin SS. Interleukin-4 and -10 gene polymorphisms and spontaneous preterm birth in multifetal gestations. Am J Obstet Gynecol. 2004 Mar;190(3):702-6. PMID: 15042002. https://www.ncbi.nlm.nih.gov/pubmed/15042002.
4. Nguyen DP, Genc M, Vardhana S, Babula O, Onderdonk A, Witkin SS. Ethnic differences of polymorphisms in cytokine and innate immune system genes in pregnant women. Obstet Gynecol. 2004 Aug;104(2):293-300. PMID: 15292002. https://www.ncbi.nlm.nih.gov/pubmed/15292002.
5. Genc MR, Vardhana S, Delaney ML, Onderdonk A, Tuomala R, Norwitz E, Witkin SS; MAP Study Group. Relationship between a toll-like receptor-4 gene polymorphism, bacterial vaginosis-related flora and vaginal cytokine responses in pregnant women. Eur J Obstet Gynecol Reprod Biol. 2004 Oct 15;116(2):152-6. PMID: 15358455. https://www.ncbi.nlm.nih.gov/pubmed/15358455.
6. Doh K, Sziller I, Vardhana S, Kovacs E, Papp Z, Witkin SS. Beta2-adrenergic receptor gene polymorphisms and pregnancy outcome. J Perinat Med. 2004;32(5):413-7. PMID: 15493717. https://www.ncbi.nlm.nih.gov/pubmed/15493717.
7. Perni SC, Vardhana S, Tuttle SL, Kalish RB, Chasen ST, Witkin SS. Fetal interleukin-1 receptor antagonist gene polymorphism, intra-amniotic interleukin-1beta levels, and history of spontaneous abortion. Am J Obstet Gynecol. 2004 Oct;191(4):1318-23. PMID: 15507960. https://www.ncbi.nlm.nih.gov/pubmed/15507960.
8. Genc MR, Onderdonk AB, Vardhana S, Delaney ML, Norwitz ER, Tuomala RE, Paraskevas LR, Witkin SS; MAP Study Group. Polymorphism in intron 2 of the interleukin-1 receptor antagonist gene, local midtrimester cytokine response to vaginal flora, and subsequent preterm birth. Am J Obstet Gynecol. 2004 Oct;191(4):1324-30. PMID: 15507961. https://www.ncbi.nlm.nih.gov/pubmed/15507961.
9. Kalish RB, Vardhana S, Gupta M, Perni SC, Chasen ST, Witkin SS. Polymorphisms in the tumor necrosis factor-alpha gene at position -308 and the inducible 70 kd heat shock protein gene at position +1267 in multifetal pregnancies and preterm premature rupture of fetal membranes. Am J Obstet Gynecol. 2004 Oct;191(4):1368-74. PMID: 15507967. https://www.ncbi.nlm.nih.gov/pubmed/15507967.
10. Perni SC, Vardhana S, Korneeva I, Tuttle SL, Paraskevas LR, Chasen ST, Kalish RB, Witkin SS. Mycoplasma hominis and Ureaplasma urealyticum in midtrimester amniotic fluid: association with amniotic fluid cytokine levels and pregnancy outcome. Am J Obstet Gynecol. 2004 Oct;191(4):1382-6. PMID: 15507969. https://www.ncbi.nlm.nih.gov/pubmed/15507969.
11. Kalish RB, Nguyen DP, Vardhana S, Gupta M, Perni SC, Witkin SS. A single nucleotide A>G polymorphism at position -670 in the Fas gene promoter: relationship to preterm premature rupture of fetal membranes in multifetal pregnancies. Am J Obstet Gynecol. 2005 Jan;192(1):208-12. PMID: 15672026. https://www.ncbi.nlm.nih.gov/pubmed/15672026.
12. Gerber S, Vardhana S, Meagher-Villemure K, Vial Y, Hohlfeld P, Witkin SS. Association between fetal interleukin-1 receptor antagonist gene polymorphism and unexplained fetal death. Am J Obstet Gynecol. 2005 Oct;193(4):1472-7. PMID: 16202742. https://www.ncbi.nlm.nih.gov/pubmed/16202742.
13. Perni SC, Vardhana S, Kalish R, Chasen S, Witkin SS. Clara cell protein 16 concentration in mid-trimester amniotic fluid: association with fetal gender, fetal G>A +38 CC16 gene polymorphism and pregnancy outcome. J Reprod Immunol. 2005 Dec;68(1-2):85-90. PMID: 16236364. https://www.ncbi.nlm.nih.gov/pubmed/16236364.
14. Kalish RB, Vardhana S, Normand NJ, Gupta M, Witkin SS. Association of a maternal CD14 -159 gene polymorphism with preterm premature rupture of membranes and spontaneous preterm birth in multi-fetal pregnancies. J Reprod Immunol. 2006 Jun;70(1-2):109-17. PMID: 16236364. https://www.ncbi.nlm.nih.gov/pubmed/16236364.
15. Genç MR, Vardhana S, Delaney ML, Witkin SS, Onderdonk AB; MAP Study Group. TNFA-308G>A polymorphism influences the TNF-alpha response to altered vaginal flora. Eur J Obstet Gynecol Reprod Biol. 2007 Oct;134(2):188-91. PMID: 17123692. https://www.ncbi.nlm.nih.gov/pubmed/17123692.
16. Kirchhof MG, Chau LA, Lemke CD, Vardhana S, Darlington PJ, Márquez ME, Taylor R, Rizkalla K, Blanca I, Dustin ML, Madrenas J. Modulation of T cell activation by stomatin-like protein 2. J Immunol. 2008 Aug 1;181(3):1927-36. PMID: 18641330. https://www.ncbi.nlm.nih.gov/pubmed/18641330.
17. Tseng SY, Waite JC, Liu M, Vardhana S, Dustin ML. T cell-dendritic cell immunological synapses contain TCR-dependent CD28-CD80 clusters that recruit protein kinase C theta. J Immunol. 2008 Oct 1;181(7):4852-63. PMID: 18802089. https://www.ncbi.nlm.nih.gov/pubmed/18802089.
18. Vardhana S, Dustin M. Supported Planar Bilayers for the Formation of Study of Immunological Synapses and Kinapse. J Vis Exp. 2008 Sep 15;(19). PMID: 19066534. https://www.ncbi.nlm.nih.gov/pubmed/19066534.
19. Ilani T, Vasiliver-Shamis G, Vardhana S, Bretscher A, Dustin ML. T cell antigen receptor signaling and immunological synapse stability require myosin IIA. Nat Immunol. 2009 May;10(5):531-9. PMID: 19349987. https://www.ncbi.nlm.nih.gov/pubmed/19349987.
20. Kaizuka Y, Douglass AD, Vardhana S, Dustin ML, Vale RD. The coreceptor CD2 uses plasma membrane microdomains to transduce signals in T cells. J Cell Biol. 2009 May 4;185(3):521-34. PMID: 19398758. https://www.ncbi.nlm.nih.gov/pubmed/19398758.
21. Srivastava S, Di L, Zhdanova O, Li Z, Vardhana S, Wan Q, Yan Y, Varma R, Backer J, Wulff H, Dustin ML, Skolnik EY. The class II phosphatidylinositol 3 kinase C2beta is required for the activation of the K+ channel Kca3.1 and CD4 T-cells. Mol Biol Cell. 2009 Sep;20(17):3783-91. PMID: 19587117. https://www.ncbi.nlm.nih.gov/pubmed/19587117.
22. Chen HY, Fermin A, Vardhana S, Weng IC, Lo KF, Chang EY, Maverakis E, Yang RY, Hsu DK, Dustin ML, Liu FT. Galectin-3 negatively regulates TCR-mediated CD4+ T-cell activation at the immunological synapse. Proc Natl Acad Sci U S A. 2009 Aug 25;106(34):14496-501. PMID: 19706535. https://www.ncbi.nlm.nih.gov/pubmed/19706535.
23. Vardhana S, Choudhuri K, Varma R, Dustin ML. Essential role of ubiquitin and TSG101 protein in formation and function of the central supramolecular activation cluster. Immunity. 2010 Apr 23;32(4):531-40. PMID: 20399684. https://www.ncbi.nlm.nih.gov/pubmed/20399684.
24. Schubert DA, Gordo S, Sabatino JJ Jr, Vardhana S, Gagnon E, Sethi DK, Seth NP, Choudhuri K, Reijonen H, Nepom GT, Evavold BD, Dustin ML, Wucherpfennig KW. Self-reactive human CD4 T cell clones form unusual immunological synapses. J Exp Med. 2012 Feb 13;209(2):335-52. PMID: 22312112. https://www.ncbi.nlm.nih.gov/pubmed/22312112.
25. Christie DA, Kirchhof MG, Vardhana S, Dustin ML, Madrenas J. Mitochondrial and plasma membrane pools of stomatin-like protein 2 coalesce at the immunological synapse during T cell activation. PloS One. 2012;7(5):e37144. PMID: 22623988. https://www.ncbi.nlm.nih.gov/pubmed/22623988.
26. Kumari S, Vardhana S, Cammer M, Curado S, Santos L, Sheetz MP, Dustin ML. T Lymphocyte Myosin IIA is Required for Maturation of the Immunological Synapse. Front Immunol. 2012;3:230. PMID: 22912631. https://www.ncbi.nlm.nih.gov/pubmed/22912631.
27. Waite JC, Vardhana S, Shaw PJ, Jang JE, McCarl CA, Cameron TO, Feske S, Dustin ML. Interference with Ca(2+) release activated Ca(2+) (CRAC) channel function delays T-cell arrest in vivo. Eur J Immunol. 2013; 43(12): 3343-54. PMID: 23939929. https://www.ncbi.nlm.nih.gov/pubmed/23939929.
28. Satlin MJ, Vardhana S, Soave R, Shore TB, Mark TM, Jacobs SE, Walsh TJ, Gergis U. Impact of Prophylactic Levofloxacin on Rates of Bloodstream Infection and Fever in Neutropenic Patients with Multiple Myeloma Undergoing Autologous Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2015 Oct; 21(10): 1808-14. PMID: 26150022. https://www.ncbi.nlm.nih.gov/pubmed/26150022.
29. Vardhana S, Sauter CS, Matasar MJ, Zelenetz AD, Galasso N, Woo KM, Zhang Z, Moskowitz CH. Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era. Br J Haematol. 2017 Feb; 176(4): 591-599. PMID: 27982423. https://www.ncbi.nlm.nih.gov/pubmed/27982423.
30. Finley LW*, Vardhana S* (co-first author), Carey BW*, Koche R, Chen Y, Alonso-Curbelo D, Wen D, King B, Radler MR, Rafii S, Lowe SW, Allis CD, Thompson CB. Pluripotency transcription factors and Tet1/2 maintain Brd4-independent stem cell identity. Nat Cell Biol. 2018 May; 20(5): 565-574. PMID: 29662175. https://www.ncbi.nlm.nih.gov/pubmed/29662175
31. Kumar A, Vardhana S, Moskowitz AJ, Porcu P, Dogan A, Dubovsky JA, Matasar MJ, Zhang Z, Younes A, Horwitz SM. Pilot Trial of Ibrutinib in patients with relapsed or refractory T-cell lymphoma. Blood Adv. 2018 Apr 24; 2(8): 871-876. PMID: 29669753. https://www.ncbi.nlm.nih.gov/pubmed/29669753
32. Vardhana S, Hamlin PA, Yang J, Zelenetz A, Sauter CS, Matasar MJ, Ni A, Yahalom J, Moskowitz CH. Outcomes of relapsed and refractory primary mediastinal (thymic) diffuse large B-cell lymphoma treated with second-line therapy and intent to transplant. Biol Blood Marrow Transplant. 2018 Jun 15. PMID 29909154. https://www.ncbi.nlm.nih.gov/pubmed/29909154
33. Vardhana S, Arnold PK, Rosen BP, Chen Y, Carey BW, Huangfu D, Fontaine CC, Thompson CB, Finley LWS. Glutamine independence is a selectable feature of pluripotent stem cells. Nat Metab. 2019 Jul;1(7):676-687. PMID 31511848. https://www.ncbi.nlm.nih.gov/pubmed/31511848
34. Cable J, Finley L, Tu BP, Patti GJ, Oliver TG, Vardhana S, Mana M, Ericksen R, Khare S, DeBerardinis R, Stockwell BR, Edinger A, Haigis M, Kaelin W. Leveraging insights into cancer metabolism – a symposium report. Ann N Y Acad Sci. 2020 Feb;1462(1):5-13. PMID 31792987. https://www.ncbi.nlm.nih.gov/pubmed/31792987
35. Maio M, Hamid O, Larkin J, Covre A, Altomonte M, Calabro L, Vardhana SA, Robert C, Ibrahim R, Anichini A, Wolchok JD, Giacomo AMD. Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era. Clin Cancer Res. 2020 Jun 15. Doi: 10.11158/1078-0432.CCR-20-1657. PMID: 32540850. https://www.ncbi.nlm.nih.gov/pubmed/32540850
36. Vardhana S, Hwee M, Berisa M, Wells DK, Yost KE, King B, Smith M, Herrera PS, Chang HY, Satpathy AT, van den Brink M, Cross JR, Thompson CB. Impaired mitochondrial oxidative phosphorylation limits the self-renewal of T-cells exposed to persistent antigen. Nat Immunol 2020, July 13. Doi: 10.1038/s41590-020-0725-2. PMID 32661364. https://www.ncbi.nlm.nih.gov/pubmed/32661364
37. Shah GL, DeWolf S, Lee YJ, Tamari R, Dahi PB, Lavery JA, Ruiz JD, Devlin SM, Cho C, Peled JU, Politikos I, Scordo M, Babady NE, Jain T, Vardhana S, Daniyan AF, Sauter CS, Barker JN, Giralt SA, Goss C, Maslak P, Hohl TM, Kamboj M, Ramanathan L, van den Brink MR, Papadopoulos EB, Papanicolaou GA, Perales MA. Favorable outcomes of COVID-19 in recipients of hematopoietic cell transplantation. J Clin Invest. 2020 Sep 8: 141777. PMID 32897885. https://pubmed.ncbi.nlm.nih.gov/32897885/
38. Pavlova NN, King B, Josselsohn RH, Violante S, Macera VL, Vardhana SA, Cross JR, Thompson CB. Translation in amino-acid-poor environments is limited by tRNAGln charging. Elife. 2020 Dec8;9:e62307. PMID: 33289483. https://pubmed.ncbi.nlm.nih.gov/33289483/
39. Scharf A, Voight L, Vardhana S, Matsoukas K, Wall LM, Arevalo M, Diamond LC. What should clinicians do when a patient’s autonomy undermines her being treated equitably? AMA J Ethics. 2021 Feb 1;23(2):E97-108. PMID 33635189. https://pubmed.ncbi.nlm.nih.gov/33635189
40. Jee J, Stonestrom AJ, Devlin S, Nguyentran T, Wills B, Narendra V, Foote MB, Lumish M, Vardhana S, Pastores SM, Korde N, Patel D, Horwitz S, Scordo M, Daniyan AF. Oncologic immunomodulatory agents in patients with cancer and COVID-19. Sci Rep. 2021 Mar 1;11(1):4814. PMID 33649382. https://www.ncbi.nlm.nih.gov/33649382.
41. Bange EM, Han NA, Wileyto P, Kim JY, Gouma S, Robinson J, Greenplate AR, Hwee MA, Porterfield F, Owoyemi O, Naik K, Zheng C, Galantino M, Weisman AR, Ittner CAG, Kugler EM, Baxter AE, Oniyide O, Agyekum RS, Dunn TG, Jones TK, Giannini HM, Weirick ME, McAllister CM, Babady NE, Kumar A, Widman AJ, DeWolf S, Boutemine SR, Roberts C, Budzik KR, Tollett S, Wright C, Perloff T, Sun L, Mathew D, Giles JR, Oldridge DA, Wu JE, Alanio C, Adamski S, Garfall AL, Vella LA, Kerr SJ, Cohen JV, Oyer RA, Massa R, Maillard IP, Maxwell KN, Reilly JP, Maslak PG, Vonderheide RH, Wolchok JD, Hensley SE, Wherry EJ, Meyer NJ, DeMichele AM, Vardhana SA*, Mamtani R*, Huang AC*. CD8(+) T cells contribute to survival in patients with COVID-19 and hematologic cancer. Nat Med. 2021 May 20. PMID: 34017137. https://www.ncbi.nlm.nih.gov/34017137. *equal contribution #corresponding author
42. Chung DJ, Shah GL, Devlin SM, Ramanathan LV, Doddi S, Pessin MS, Hoover E, Marcello LT, Young JC, Boutemine SR, Serrano E, Sharan S, Momotaj S, Margetich L, Bravo CD, Papanicolao GA, Kamboj M, Mato AR, Roeker LE, Hultcrantz M, Mailankody S, Lesokhin AM, Vardhana SA*, Knorr DA*. Disease- and Therapy-Specific Impact on Humoral Immune Responses to COVID-19 Vaccination in Hematologic Malignancies. Blood Cancer Discov. 2021 Sep 13;2(6):568-576. doi: 10.1158/2643-3230.BCD-21-0139. PMID: 34778797
43. Tamari R, Politikos I, Knorr DA, Vardhana SA, Young JC, Marcello LT, Doddi S, Devlin SM, Ramanathan LV, Pessin MS, Dunn E, Palazzo M, Bravo CD, Papanicolaou GA, Kamboj M, Perales MA, Chung DJ, Shah GL. Predictors of Humoral Response to SARS-CoV-2 Vaccination after Hematopoietic Cell Transplantation and CAR T-cell Therapy. Blood Cancer Discov. 2021 Sep 13;2(6):577-585. doi: 10.1158/2643-3230.BCD-21-0142. PMID: 34778798
44. Lee CY, Shah MK, Hoyos D, Solovyov A, Douglas M, Taur Y, Maslak PG, Babady NE, Greenbaum B, Kamboj M, Vardhana SA. Prolonged SARS-CoV-2 infection in patients with lymphoid malignancies. Cancer Discov. 2022 Jan;12(1):62-73. doi: 10.1158/2159-8290.CD-21-1033. PMID 34753749. https://pubmed.ncbi.nlm.nih.gov/34753749/
45. Moskowitz AJ, Shah G, Schöder H, Ganesan N, Drill E, Hancock H, Davey T, Perez L, Ryu S, Sohail S, Santarosa A, Galasso N, Neuman R, Liotta B, Blouin W, Kumar A, Lahoud O, Batlevi CL, Hamlin P, Straus DJ, Rodriguez-Rivera I, Owens C, Caron P, Intlekofer AM, Hamilton A, Horwitz SM, Falchi L, Joffe E, Johnson W, Lee C, Palomba ML, Noy A, Matasar MJ, Pongas G, Salles G, Vardhana S, Sanin BW, von Keudell G, Yahalom J, Dogan A, Zelenetz AD, Moskowitz CH. Phase II Trial of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin as Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma. J Clin Oncol. 2021 Oct 1;39(28):3109-3117. PMID: 34170745.
46. Moskowitz AJ, Ghione P, Jacobsen ED, Ruan J, Schatz JH, Noor SJ, Myskowski PL, Vardhana SA, Ganesan N, Hancock H, Davey T, Perez L, Ryu S, Santarosa AM, Dowd J, Obadi O, Pomerantz LD, Yi N, Sohail S, Galasso N, Neuman R, Liotta B, Blouin W, Baik J, Geyer MB, Noy A, Straus DJ, Kumar P, Dogan A, Hollmann TJ, Drill E, Rademaker J, Schöder H, Inghirami GG, Weinstock DM, Horwitz SM. Phase II biomarker-driven study of ruxolitinib demonstrates effectiveness of JAK/STAT targeting in T-cell lymphomas. Blood. 2021 Oct 15:blood.2021013379. doi: 10.1182/blood.2021013379. PMID: 34653242
47. Docampo MD, Burgos da Silva M, Lazrak A, Nichols KB, Lieberman SR, Slingerland AE, Armijo GK, Shono Y, Nguyen CL, Monette S, Dwomoh E, Lee N, Geary CD, Perobelli SM, Smith M, Markey KA, Vardhana SA, Kousa AI, Zamir E, Greenfield I, Sun JC, Cross JR, Peled JU, Jenq RR, Stein-Thoeringer C, van den Brink MRMR. Alloreactive T cells deficient of the short-chain fatty acid receptor GPR109A induce less graft-versus-host disease. Blood. 2022 Apr 14;139(15):2392-2405. doi: 10.1182/blood.2021010719. PMID: 34653248
48. Vos EL, Nakauchi M, Gönen M, Castellanos JA, Biondi A, Coit DG, Dikken JL, D’Ugo D, Hartgrink H, Li P, Nishimura M, Schattner M, Song KY, Tang LH, Uyama I, Vardhana S, Verhoeven RHA, Wijnhoven BPL, Strong VE. Risk of Lymph Node Metastasis in T1b Gastric Cancer: An International Comprehensive Analysis from the Global Gastric Group (G3) Alliance. Ann Surg. 2021 Dec 14. doi: 10.1097/SLA.0000000000005332. PMID: 34913904.
49. Belk JA, Yao W, Ly N, Freitas KA, Chen Y, Shi Q, Valencia AM, Shifrut E, Kale N, Yost KE, Duffy CV, Hwee MA, Miao Z, Ashworth A, Mackall CL, Marson A, Carnevale J, Vardhana SA, Satpathy AT. Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence. bioRxiv 2022.04.20.488974; doi: https://doi.org/10.1101/2022.04.20.488974
50. Stuver R, Shah GL, Korde NS, Roeker LE, Mato AR, Batlevi CL, Chung DJ, Doddi S, Falchi L, Gyurkocza B, Hamilton A, Lin YH, Jakubowski AA, Joffe E, Landau HL, Lin RJ, Mailankody S, Palomba ML, Park JH, Perales MA, Ponce DM, Ramanathan LV, Salles GA, Scordo M, Seo SK, Shah UA, Stein EM, Straus D, Usmani SZ, Young JW, Zelenetz AD, Noy A, Vardhana SA. Activity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies. Cancer Cell. 2022 Jun 13;40(6):590-591. PMID: 35598602. https://pubmed.ncbi.nlm.nih.gov/35598602/
51. Lyudovyk O, Kim JY, Qualls D, Hwee MA, Lin YH, Boutemine SR, Elhanati Y, Solovyov A, Douglas M, Chen E, Babady NE, Ramanathan L, Vedantam P, Bandlamudi C, Gouma S, Wong P, Hensley SE, Greenbaum B, Huang AC, Vardhana SA. Impaired humoral immunity is associated with prolonged COVID-19 despite robust CD8 T cell responses. Cancer Cell. 2022 May 30:S1535-6108(22)00226-4. PMID: 35679859. https://pubmed.ncbi.nlm.nih.gov/35679859/
52. Belk JA, Yao W, Ly N, Freitas KA, Chen YT, Shi Q, Valencia AM, Shifrut E, Kale N, Yost KE, Duffy CV, Daniel B, Hwee MA, Miao Z, Ashworth A, Mackall CL, Marson A, Carnevale J, Vardhana SA, Satpathy AT. Genome-wide CRISPR screens of T cell exhaustion identify chromatin remodeling factors that limit T cell persistence. Cancer Cell. 2022 Jul 11; 40(7):768-786. PMID: 35750052. https://pubmed.ncbi.nlm.nih.gov/35750052/
53. Abate M, Vos E, Gonen M, Janjigian YY, Schattner M, Laszkowska M, Tang L, Maron SB, Coit DG, Vardhana S, Vanderbilt C, Strong VE. A novel microbiome signature in gastric cancer: a two independent cohort retrospective analysis. Ann Surg. 2022 Oct 1; 276(4): 605-615. PMID: 35822725. https://pubmed.ncbi.nlm.nih.gov/35822725/
54. Noy A, Vardhana SA. Discordant SARS-CoV-2 spike protein receptor binding domain IgG and neutralization after B cell depletion. Haematologica. 2022 Dec 1;107(12):2988-2989. PMID: 35950536. https://pubmed.ncbi.nlm.nih.gov/35950536/
55. Johnson WT, Ganesan N, Epstein-Peterson ZD, Moskowitz AJ, Stuver RN, Maccaro CR, Galasso N, Chang T, Khan N, Aypar U, Lewis NE, Zelenetz AD, Palomba ML, Matasar MJ, Noy A, Hamilton AM, Hamlin P, Caron PC, Straus DJ, Intlekofer AM, Lee Batlevi C, Kumar A, Owens CN, Sauter CS, Falchi L, Lue JK, Vardhana SA, Salles G, Dogan A, Schultz ND, Arcila ME, Horwitz SM. TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy. Blood Adv. 2023 Sep 12;7(17):5172-5186. PMID: 37078708. https://pubmed.ncbi.nlm.nih.gov/37078708/
56. Wang G, Lyudovyk O, Kim JY, Lin YH, Elhanati Y, Mathew D, Wherry EJ, Herati RS, Greenplate AR, Greenbaum B*, Vardhana SA*, Huang AC*. High-throughput interrogation of immune responses using the Human Immune Profiling Pipeline. STAR Protoc. 2023 May 8;4(2):102289. Online ahead of print. PMID: 37159385. https://pubmed.ncbi.nlm.nih.gov/37436885/
57. Stuver R, Drill E, Qualls D, Okwali M, Lee Batlevi C, Caron PC, Dogan A, Epstein-Peterson ZD, Falchi L, Hamlin PA, Horwitz SM, Imber BS, Intlekofer AM, Johnson WT, Khan N, Kumar A, Lahoud OB, Lue JK, Matasar MJ, Moskowitz AJ, Noy A, Owens CN, Palomba ML, Schöder H, Vardhana SA, Yahalom J, Zelenetz AD, Salles G, Straus DJ. Retrospective characterization of nodal marginal zone lymphoma. Blood Adv. 2023 Sep 12;7(17):4838-4847. PMID: 37307213. https://pubmed.ncbi.nlm.nih.gov/37436885/
58. Lareau CA, Dubois SM, Buquicchio FA, Hsieh YH, Garg K, Kautz P, Nitsch L, Praktiknjo SD, Maschmeyer P, Verboon JM, Gutierrez JC, Yin Y, Fiskin E, Luo W, Mimitou EP, Muus C, Malhotra R, Parikh S, Fleming MD, Oevermann L, Schulte J, Eckert C, Kundaje A, Smibert P, Vardhana SA, Satpathy AT, Regev A, Sankaran VG, Agarwal S, Ludwig LS. Single-cell multi-omics of mitochondrial DNA disorders reveals dynamics of purifying selection across human immune cells. Nat Genet. 2023 Jul;55(7):1198-1209. Epub 2023 Jun 29. PMID: 37386249. https://pubmed.ncbi.nlm.nih.gov/37436885/
59. Abate M, Walch H, Arora K, Vanderbilt CM, Fei T, Drebin H, Shimada S, Maio A, Kemel Y, Stadler ZK, Schmeltz J, Sihag S, Ku GY, Gu P, Tang L, Vardhana S, Berger MF, Brennan MF, Schultz ND, Strong VE. Unique Genomic Alterations and Microbial Profiles Identified in Patients With Gastric Cancer of African, European, and Asian Ancestry: A Novel Path for Precision Oncology. Ann Surg. 2023 Oct 1;278(4):506-518. Epub 2023 Jun 29. PMID: 37436885. https://pubmed.ncbi.nlm.nih.gov/37436885/
60. Stuver R, Vardhana SA, Bedmutha A, Chan KK, Mirtcheva-Trocheva R, Nosov A, Schöder H, Moskowitz A. Disease response upon cessation of methotrexate in a patient with Hodgkin lymphoma treated with pembrolizumab. Leuk Lymphoma. 2023 Oct 5:1-3. PMID: 37794809. https://pubmed.ncbi.nlm.nih.gov/37794809/
61. Stuver R, Noy A, Vardhana SA, Zelenetz AD, Moskowitz AJ. Gemcitabine plus pembrolizumab after checkpoint blockade failure as a strategy in multiply relapsed Hodgkin lymphoma. Br J Haematol. 2023 Oct 31. PMID: 37905372. https://pubmed.ncbi.nlm.nih.gov/37905372/
62. Liu Y, Sardana R, Nemirovsky D, Frosina D, Jungbluth A, Johnson WT, Vardhana SA, Arcila ME, Horwitz SM, Derkach A, Dogan A, Xiao W. Somatic mutations in FAS pathway increase hemophagocytic lymphohistiocytosis risk in T- and/or NK-cell lymphoma patients. Blood Adv. 2024 Apr 9:bloodadvances.2023011733. PMID: 38593227. https://pubmed.ncbi.nlm.nih.gov/38593227/
Reviews and Editorials:
1. Fooksman DR, Vardhana S, Vasiliver-Shamis G, Liese J, Blair DA, Waite J, Sacristán C, Victora GD, Zanin-Zhorov A, Dustin ML. Functional anatomy of T cell activation and synapse formation. Annu Rev Immunol. 2010;28:79-105. PMID: 19968559. https://www.ncbi.nlm.nih.gov/pubmed/19968559.
2. Vardhana S, Younes A. The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints. Haematologica. 2016 Jul; 101(7): 794-802. PMID: 27365459. https://www.ncbi.nlm.nih.gov/pubmed/27365459
3. Vardhana S, Cicero K, Velez MJ, Moskowitz CH. Strategies for Recognizing and Managing Immune-Mediated Adverse Events in the Treatment of Hodgkin Lymphoma with Checkpoint Inhibitors. Oncologist. 2019 Jan; 24(1): 86-95. PMID: 30082490. https://www.ncbi.nlm.nih.gov/pubmed/30082490
4. Schworer S, Vardhana S, Thompson CB. Cancer metabolism drives a stromal regenerative response. Cell Metab. 2019 Mar 5; 29(3): 576-591. PMID: 30773467. https://www.ncbi.nlm.nih.gov/pubmed/30773467
5. Vardhana S, Wolchok JD. The many faces of the anti-COVID immune response. J Exp Med 2020 June 1;217(6). PMID 32353870. https://www.ncbi.nlm.nih.gov/pubmed/32353870
6. Somarribas Patterson LF, Vardhana SA. Metabolic regulation of the cancer-immunity cycle. Trends Immunol. 2021 Oct 2:S1471-4906(21)00178-2. PMID: 34610889.
7. Akkari L, Finley SD, Ho PC, Jenkins M, Maier BB, McGranahan N, Mutebi M, Perera RM, Robles-Espinoza CD, Vardhana S, Wan L, Xu MM. Challenges and opportunities in 2021. Nat Cancer. 2021 Dec;2(12):1278-1283. doi: 10.1038/s43018-021-00294-6.PMID: 35121916
8. Vardhana S, Dustin ML. Magnesium for T cells: strong to the finish! Trends Immunol. 2022 Apr;43(4):277-279. doi: 10.1016/j.it.2022.02.004. Epub 2022 Mar 5.PMID: 35260350
9. Vardhana S, Baldo L, Morice WG 2nd, Wherry EJ. Understanding T-cell responses to COVID-19 is essential for informing public health strategies. Sci Immunol. 2022 Mar 24:eabo1303. doi: 10.1126/sciimmunol.abo1303. Online ahead of print.PMID: 35324269
10. McGary LHF, Vardhana SA. Vive la Résistance: T-cell Immunity in the Protection against SARS-CoV-2 Infection. Cancer Discov. 2022 Apr 1;12(4):892-894. doi: 10.1158/2159-8290.CD-22-0080.PMID: 35373282
11. Laracy JC, Kamboj M, Vardhana SA. Long and persistent COVID-19 in patients with hematologic malignancies: from bench to bedside. Curr Opin Infect Dis. 2022 Aug 1; 35(4):271-279. PMID: 35849516. https://pubmed.ncbi.nlm.nih.gov/35849516/
12. DeWolf S, Laracy JC, Perales MA, Kamboj M, van den Brink MRM, Vardhana S. SARS-CoV-2 in immunocompromised individuals. Immunity. 2022 Oct 11;55(10):1779-1798. PMID: 36182669. https://pubmed.ncbi.nlm.nih.gov/36182669.
13. Falchi L, Vardhana SA, Salles GA. Bispecific antibodies for the treatment of B-cell lymphoma: Promises, unknowns and opportunities. Blood. 2022 Nov 2:blood.2021011994. Online ahead of print. PMID: 36322929. https://pubmed.ncbi.nlm.nih.gov/36322929.
14. Schoenfeld JD, Vardhana SA. Not so neutral lipids: Metabolic regulation of the pre-metastatic niche. Cell Metab. 2022 Dec6;34(12):1899-1900. PMID: 36476931. https://pubmed.ncbi.nlm.nih.gov/36476931/